الصفحة 1
الصفحة 1
Messenger RNA therapeutics
Focuses on the fundamentals and applications of messenger RNA (mRNA)-based therapeutics and discusses the strengths and key challenges of this emerging class of drugs. In the past 30 years, extensive research and technological development in many areas have contributed to the emergence of in vitro transcribed mRNA as a therapeutic that has now reached clinical testing. Formulations that protect the mRNA from nucleases and accelerate its cellular uptake, combined with improvements to the mRNA molecules themselves, have been critical advancements for mRNAs to become viable therapeutics. Though once regarded as a serious impediment, the transient nature of mRNA technology is now considered a major advantage in making mRNA therapies safe and, ultimately, a potential game changer in the field of medicine. This new book in the RNA Technologies series provides a state-of-the-art overview on the emerging field of mRNA therapeutics covering essential strategies for formulation, delivery, and application. It also reviews the promising role in cancer immunotherapy, respiratory diseases, and chronic HBV infection and discusses RNA vaccines in light of the current COVID-19 pandemic. mRNA-based approaches have great potential to revolutionize molecular biology, cell biology, biomedical research, and medicine.
Hepatitis Delta Virus ; Vol. 307
Since its discovery nearly 30 years ago, hepatitis delta virus (HDV) has continued to surprise and fascinate. At 1,680 nucleotides the HDV genome is the smallest known to infect man. It is unique among animal viruses, the closest known relatives being plant viroids. To compensate for its limited protein coding capacity, HDV relies heavily on host functions and on structural features of its circular RNA genome. HDV infection depends on hepatitis B virus as a helper, and increases the severity of liver disease caused by HBV alone. There is currently neither an effective HDV vaccine nor a generally accepted useful therapy for HDV infection. This volume encompasses recent developments in HDV research, from molecular virology to genetics to experimental investigation of new therapeutic and vaccine candidates.
Drug interactions in infectious diseases : Antimicrobial drug interactions
Delivers a quick clinical resource that distills relevant drug interactions by antimicrobial drug class. The book provides informative tables on specific drug-drug interactions that include the degree and severity of the expected interaction. A mechanistic basis for drug-drug interactions is also provided to link observed interactions to pharmacologic characteristics of key drug classes. This complete resource is organized by major antibacterial, antimycobacterial, antiviral, antifungal, antimalarial, and antiprotozoal class. In line with current innovations in antimicrobial drug development, a distinct chapter on the pharmacologic management of drug interactions in hepatitis B virus (HBV) and hepatitis C virus (HCV)-related infections is included. Two new chapters are dedicated to the management of human immunodeficiency virus (HIV) drug-drug interactions given the breadth of antiretroviral class-specific effects. This comprehensive review of known drug interactions and strategies to manage them is an invaluable resource to all health care practitioners.
